耳鼻咽喉科・頭頸部外科94巻7号

2022年06月発行

特集 この1冊ですべてがわかる 頭頸部がんの支持療法と緩和ケア

《治療法別支持療法》

分子標的薬投与時の支持療法

著者： 小山泰司¹

所属機関： ¹神戸大学医学部附属病院腫瘍・血液内科

ページ範囲：P.514 - P.519

文献概要

POINT

●分子標的薬では特徴的な副作用がみられる。

●支持療法は治療の継続性に関わるため重要である

●各薬剤の特徴を捉えて患者指導を行う。

参考文献

1）Vermorken JB, et al：Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359：1116-1127, 2008

2）Hitt R, et al：Phase Ⅱ study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23：1016-1022, 2012

3）Tahara M, et al：Phase Ⅱ trial of combination treatment with paclitaxel, carboplatin and cetuximab（PCE）as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck（CSPOR-HN02）. Ann Oncol 29：1004-1009, 2008

4）Enokida T, et al：Paclitaxel plus cetuximab as 1st line chemotherapy in platinum-based chemoradiotherapy-refractory patients with squamous cell carcinoma of the head and neck. Front Oncol 8：339, 2018

5）Guo Y, et al：Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck：Results of an open-label, single-arm, multicenter trial. Head Neck 37：1081-1087, 2015

6）Yoshino T, et al：Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck：results of a phase Ⅱ trial. Jpn J Clin Oncol 43：524-531, 2013

7）Matsuda A, et al：Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer：a meta-analysis. Anticancer Res 40：3469-3476, 2020

8）Bonner JA, et al：Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354：567-578, 2006

注射液100mg 適正使用ガイド 第4版—頭頸部癌［2022年1月24日閲覧］

10）Lacouture ME, et al：Skin toxicity evaluation protocol with panitumumab（STEPP）, a phase Ⅱ, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28：1351-1357, 2010

11）Park JH, et al：Duration of oral antibiotics administration for cetuximab-induced acneiform eruption. Dermatology 237：457-463, 2021

12）Hofheinz RD, et al：EVITA-a double-blind, vehicle-controlled, randomized phase Ⅱ trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol 29：1010-1015, 2018

13）Chayahara N, et al：Adapalene gel 0.1％ versus placebo as prophylaxis for anti-epidermal growth factor receptor-induced acne-like rash：a randomized left-right comparative evaluation（APPEARANCE）. Oncologist 24：885-e413, 2019

14）Brose MS, et al：Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer：a randomised, double-blind, phase 3 trial. Lancet 384：319-328, 2014

15）Schlumberger M, et al：Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372：621-630, 2015

16）Kiyota N, et al：Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106：1714-1721, 2015

17）Wells SA Jr, et al：Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer：a randomized, double-blind phase Ⅲ trial. J Clin Oncol 30：134-141, 2012

18）Ren Z, et al：Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33：894-900, 2015

19）Wu S, et al：Incidence and risk of hypertension with sorafenib in patients with cancer：a systematic review and meta-analysis. Lancet Oncol 9：117-123, 2008

錠200mg適正使用ガイド—甲状腺癌編［2022年1月24日閲覧］

錠100mg適正使用ガイド［2022年1月24日閲覧］

適正使用ガイド—甲状腺癌［2022年1月24日閲覧］

23）Brinda BJ, et al：Anti-VEGF-induced hypertension：a review of pathophysiology and treatment options. Curr Treat Options Cardio Med 18：33, 2016

24）Izzedine H, et al：VEGF signalling inhibition-induced proteinuria：mechanisms, significance and management. Eur J Cancer 46：439-448, 2010

25）Izzedine H, et al：Kidney diseases associated with anti-vascular endothelial growth factor（VEGF）：an 8-year observational study at a single center. Medicine（Baltimore）93：333-339, 2014

26）Gressett SM, et al：Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43：490-501, 2009

27）Hiremath S, et al：Renin angiotensin system blockade in kidney transplantation：a systematic review of the evidence. Am J Transplant 7：2350-2360, 2007

28）Li AY, et al：RET fusions in solid tumors. Cancer Treat Rev 81：101911, 2019

29）Wirth LJ, et al：Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383：825-835, 2020

30）Varga ZV, et al：Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 309：H1453-H1467, 2015

31）Di Cosimo S：Heart to heart with trastuzumab：a review on cardiac toxicity. Target Oncol 6：189-195, 2011

［2022年1月24日閲覧］

33）Doebele RC, et al：Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours：integrated analysis of three phase 1-2 trials. Lancet Oncol 21：271-282, 2020

34）Drilon A, et al：Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378：731-739, 2018

35）Hong DS, et al：Larotrectinib in patients with TRK fusion-positive solid tumours：a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21：531-540, 2020